Arrivent Biopharma Inc (AVBP) Stock Price, Quote & News

Company Profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment o...

Industry: Biotechnology

Sector: Healthcare

Phone: 628 277 4836

Website: arrivent.com

Address:

18 Campus Boulevard, Suite 100, Newtown Square, United States

MikeBob15 Sep. 14 at 5:50 PM

$AVBP Can someone please tell me how a stock with a billion and a half market cap and five hundred thousand shares , daily volume has a spread of about .20???

0 · Reply

justiceforb_85 Sep. 11 at 12:01 AM

$AVBP wonder if there'll be data release at the WCLC conference.

0 · Reply

judgeyoung2 Sep. 9 at 7:09 PM

$AVBP look at all the itm call flow for October 🤔

0 · Reply

Quantumup Sep. 1 at 1:07 PM

JPMorgan🏁 $BLSM and said -- We are initiating coverage of BlossomHill Therapeutics (BLSM) with an Overweight rating and a Dec-2027 price target of $28. $AVBP $CGEM MRK DSNKY BDTX ORIC AZN JNJ Here's what JPMorgan went on to say: https://x.com/Quantumup1/status/2094774045099139272?s=20

0 · Reply

LivermoresGhost Aug. 26 at 4:22 AM

$CVAT $CVAT BUYOUT ALERT: Cavitation Technologies CVAT has execute a buyout for this company at 35 million $. This translate to 11.2c per share, you can finds this on the company SEC filing. The stock right now trades 4.3c, the buyout is for 11.2c. The buyer EGS, has already shown proof of funds, the Definitive Purchase Agreement has already been sign, and on Monday they will file the Tender Offer for submit your shares to the company. Buyout sp: 11.2c Current sp: 4.3c 270% Return on Investment, Tender will start this week!!!!!!!!!!!!!!!!!! https://in.investing.com/news/stock-market-news/cavitation-technologies-agrees-to-35-million-acquisition-deal-93CH-5559884 Here is the company thats buying Cavitation, they have 20 billion Euros Capital Backing. https://euroguarantee.lu/ $LITB $FGI $CIR $AVBP

0 · Reply

StochAlpha Aug. 20 at 12:05 PM

Sector Heat Map · Aug 20 · 12 Signals. Real Estate Leads. Thin cut today. Real Estate leads with 4 signals $FTRE showing up there. Healthcare and Tech each very light. $AVBP on the healthcare side, $AAPL the lone tech name. Consumer Discretionary, Energy, Industrials, dark. Market is not giving a lot to work with today. What's there is defensive. See Top 5 Buys / Sells posted a few minutes ago.

0 · Reply

27R Aug. 18 at 3:34 PM

$AVBP Buckle up — earnings after the close today.

0 · Reply

Quantumup Aug. 17 at 11:36 AM

H.C. Wainwright⬆️ $AVBP's PT to $47 and reiterated Buy. $CGON $ORIC JNJ AZN SMMT BDTX Here's what H.C. Wainwright said in its note to investors: https://x.com/Quantumup1/status/2089314943409574282?s=20

0 · Reply

Monkey7779192 Aug. 12 at 11:16 PM

$AVBP They delayed it. Something isnt right.

2 · Reply

justiceforb_85 Aug. 12 at 8:34 PM

$AVBP not quite sure what to make of delay in data release. Still remain optimistic.

0 · Reply

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

ArriVent BioPharma Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

ArriVent Biopharma assumed with a Buy at BTIG

2026-03-11T20:28:14.000Z - 6 months ago

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential

2025-12-10T11:46:01.000Z - 9 months ago

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 8:00 AM EDT - 1 year ago

ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jul 1, 2025, 11:15 PM EDT - 1 year ago

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

Jun 20, 2025, 4:05 PM EDT - 1 year ago

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Nov 14, 2024, 8:00 AM EST - 1 year ago

ArriVent BioPharma Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

ArriVent BioPharma Earnings release: Q3 2024

Sep 9, 2024, 12:05 PM EDT - 2 years ago

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

Aug 15, 2024, 7:01 AM EDT - 2 years ago

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

Jun 5, 2024, 7:00 AM EDT - 2 years ago

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

Mar 28, 2024, 4:05 PM EDT - 2 years ago

ArriVent BioPharma Reports Full Year 2023 Financial Results

MikeBob15 Sep. 14 at 5:50 PM

$AVBP Can someone please tell me how a stock with a billion and a half market cap and five hundred thousand shares , daily volume has a spread of about .20???

0 · Reply

justiceforb_85 Sep. 11 at 12:01 AM

$AVBP wonder if there'll be data release at the WCLC conference.

0 · Reply

judgeyoung2 Sep. 9 at 7:09 PM

$AVBP look at all the itm call flow for October 🤔

0 · Reply

Quantumup Sep. 1 at 1:07 PM

0 · Reply

LivermoresGhost Aug. 26 at 4:22 AM

0 · Reply

StochAlpha Aug. 20 at 12:05 PM

0 · Reply

27R Aug. 18 at 3:34 PM

$AVBP Buckle up — earnings after the close today.

0 · Reply

Quantumup Aug. 17 at 11:36 AM

0 · Reply

Monkey7779192 Aug. 12 at 11:16 PM

$AVBP They delayed it. Something isnt right.

2 · Reply

justiceforb_85 Aug. 12 at 8:34 PM

$AVBP not quite sure what to make of delay in data release. Still remain optimistic.

0 · Reply

judgeyoung2 Aug. 12 at 8:26 PM

$AVBP from the beginning of the year to the middle to the second half lol

1 · Reply

justiceforb_85 Aug. 10 at 9:57 PM

$AVBP patiently waiting for firmonertinib data.

0 · Reply

justiceforb_85 Aug. 6 at 9:55 PM

$AVBP hopefully an update at next quarterly report?

0 · Reply

justiceforb_85 Aug. 4 at 1:48 AM

$AVBP still waiting on data. Good luck to all longs.

0 · Reply

Market Cap	1.43B
Revenue (ttm)	0.00
Net Income (ttm)	-166.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	538,338
Avg Vol	474,888
Day's Range	N/A - N/A
Shares Out	49.31M
Stochastic %K	26%
Beta	1.35
Analysts	Strong Sell
Price Target	$44.82